Blackstone’s bet on cell and gene therapy sends Cryoport shares skyward

For Blackstone, investing in Cryoport offers a means to ride the rapid and sustained growth of cell and gene therapy without taking on any idiosyncratic risk. 

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this